Repare Therapeutics Inc. Common Shares - RPTX STOCK NEWS

Repare Therapeutics presented initial data from its ongoing Phase 1/2 TRESR clinical trial for camonsertib (RP-3500), an ATR inhibitor, in combination with PARPis at the 2023 AACR Annual Meeting. The trials show a 48% clinical benefit rate across various tumor types, especially in late-line ovarian cancer with a 58% clinical benefit rate and a median progression-free survival of about 7 months. Early ctDNA responses indicated a strong antitumor activity, with 66% of evaluable patients responding positively. The treatment showed a favorable safety profile with manageable toxicities. Repare is focused on optimizing doses and expanding studies in different tumor types as part of its collaboration with Roche.

Repare Therapeutics Inc. (Nasdaq: RPTX) announced that data from Phase I/II trials of camonsertib in combination with PARP inhibitors has been selected for presentation at the 2023 AACR Annual Meeting in Orlando, Florida, from April 14-19, 2023. The presentation will highlight safety and efficacy results in patients with solid tumors with DNA damage response alterations, featuring Dr. Timothy Yap. Additionally, two poster presentations will characterize genomic features in ovarian and uterine cancers. Repare's SNIPRx® platform enables the development of precision oncology therapies targeting genomic instability, showcasing its commitment to innovative cancer treatment.

Repare Therapeutics reported its financial results for Q4 and full year 2022, emphasizing growth in its oncology pipeline. The company secured a collaboration with Roche for camonsertib, received FDA Fast Track designation for RP-6306, and expects significant clinical trial data in 2023. Revenue from collaboration agreements rose to $131.8 million in 2022, up from $7.6 million in 2021. Net loss was $31.7 million for Q4 2022, marking an increase from $28.3 million in Q4 2021. Cash and equivalents totaled $343.9 million, projected to support operations until 2026. Repare plans to advance multiple clinical programs throughout 2023.

Repare Therapeutics Inc. (Nasdaq: RPTX) announced its participation in two investor conferences: the Guggenheim Oncology Conference on February 9, 2023, at 3:20 p.m. ET in New York, and the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 9:50 a.m. ET in Boston. Investors can access live webcasts of the events via the Company’s website, with replays available for 30 days. Repare is focused on precision oncology, using its proprietary SNIPRx® platform for developing targeted cancer therapies, including ongoing Phase 1 trials of RP-6306 and camonsertib (RP-3500), and additional preclinical programs.

Repare Therapeutics Inc. (NASDAQ: RPTX) announced a $1.5 million research service payment from Ono Pharmaceutical Co., Ltd. This payment is part of their 2019 Strategic Partnership Agreement, linked to the Polθ program (RP-2119). The funding indicates a key milestone as Repare progresses towards IND-enabling studies and prepares for clinical trials anticipated to start in summer 2023. To date, the Ono Agreement has facilitated approximately $8.1 million in funding for Repare, evidencing ongoing collaboration and financial support for its oncology research initiatives.